Method, carried out by computer, making it possible to identify antibodies capable of binding to the same target, the method comprising: - providing a database comprising the characterization of at least 100 antibodies, each antibody being characterized by a simplified sequence and a secondary structure of the CDRs (complementarity-determining regions) CDR1, CDR2 and CDR3 for each variable domain of an antibody of the database, and; ▪ the simplified sequence being a translated sequence in which each amino acid of the initial sequence of the CDRs is replaced by a code representing a category of amino acids, the categories being based on the physicochemical characteristics of the amino acids, the number of categories being between 4 and 10; and the categories being chosen from the size of the amino acids, their hydrophobicity, their polarity, their charge, their aromatic nature and combinations of these characteristics; ▪ the secondary structure being a translated sequence in which each amino acid of the initial sequence of the CDRs is replaced by a code representing a type of secondary structure, the number of types of secondary structure being between 3 and 8 and the types of secondary structure being chosen from a 3 10 helix, an α helix, a π helix, a tight turn, a β strand, a residue in a β-bridge, a turn or an absence of secondary structure; - providing a simplified sequence and a secondary structure of the CDRs CDR1, CDR2 and CDR3 for a variable domain of a reference antibody; - calculating a score for similarity between the variable domain of the reference antibody and a variable domain of a test antibody from the database based on the simplified sequence of their CDRs and on the secondary structure of their CDRs by identifying subsequences common to the CDRs of the reference antibody and of the test antibody; and - selecting the test antibody if the similarity score is such that it predicts that the test antibody and the reference antibody are capable of binding to the same target, the test antibody selected being referred to as similar antibody. - providing a database comprising the characterization of at least 100 antibodies, each antibody being characterized by a simplified sequence and a secondary structure of the CDRs (complementarity-determining regions) CDR1, CDR2 and CDR3 for each variable domain of an antibody of the database, and; ▪ the simplified sequence being a translated sequence in which each amino acid of the initial sequence of the CDRs is replaced by a code representing a category of amino acids, the categories being based on the physicochemical characteristics of the amino acids, the number of categories being between 4 and 10; and the categories being chosen from the size of the amino acids, their hydrophobicity, their polarity, their charge, their aromatic nature and combinations of these characteristics; ▪ the secondary structure being a translated sequence in which each amino acid of the initial sequence of the CDRs is replaced by a code representing a type of secondary structure, the number of types of secondary structure being between 3 and 8 and the types of secondary structure being chosen from a 3 10 helix, an α helix, a π helix, a tight turn, a β strand, a residue in a β-bridge, a turn or an absence of secondary structure; ▪ the simplified sequence being a translated sequence in which each amino acid of the initial sequence of the CDRs is replaced by a code representing a category of amino acids, the categories being based on the physicochemical characteristics of the amino acids, the number of categories being between 4 and 10; and the categories being chosen from the size of the amino acids, their hydrophobicity, their polarity, their charge, their aromatic nature and combinations of these characteristics; ▪ the secondary structure being a translated sequence in which each amino acid of the initial sequence of the CDRs is replaced by a code representing a type of secondary structure, the number of types of secondary structure being between 3 and 8 and the types of secondary structure being chosen from a 3 10 helix, an α helix, a π helix, a tight turn, a β strand, a residue in a β-bridge, a turn or an absence of secondary structure; - providing a simplified sequence and a secondary structure of the CDRs CDR1, CDR2 and CDR3 for a variable domain of a reference antibody; - calculating a score for similarity between the variable domain of the reference antibody and a variable domain of a test antibody from the database based on the simplified sequence of their CDRs and on the secondary structure of their CDRs by identifying subsequences common to the CDRs of the reference antibody and of the test antibody; and - selecting the test antibody if the similarity score is such that it predicts that the test antibody and the reference antibody are capable of binding to the same target, the test antibody selected being referred to as similar antibody.